Silence Therapeutics plc
SLNCF
$0.95
$0.451490.53%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 129.41% | -79.05% | -725.23% | 86.39% | -67.29% |
| Total Depreciation and Amortization | 0.07% | -0.27% | -1.38% | 8.10% | -11.05% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -229.27% | 1,444.01% | -95.48% | 167.42% | 990.31% |
| Change in Net Operating Assets | -4,287.81% | -95.02% | 164.60% | -984.62% | -139.43% |
| Cash from Operations | -7.99% | -321.19% | 36.10% | 34.25% | -134.32% |
| Capital Expenditure | -3.13% | 24.50% | -- | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 266.51% | -4,929.52% | 101.57% | -4,214.00% | -104.39% |
| Cash from Investing | 266.05% | -5,529.06% | 101.40% | -4,214.37% | -104.39% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 473.06% | 49.48% | -- | -- | 440.61% |
| Issuance of Common Stock | -- | 571.50% | -99.16% | 874.57% | -9.83% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 2,769.88% | -- | 100.00% | -860.07% | 227.38% |
| Cash from Financing | -82.01% | 626.83% | -99.20% | 968.21% | -17.74% |
| Foreign Exchange rate Adjustments | 200.34% | -3,228.18% | -1,186.18% | -103.05% | -69.83% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 168.91% | -1,271.82% | -106.02% | 3,010.17% | -106.98% |